Transenterix Inc(NYSEMKT:TRXC) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 5, 2016. Company reported revenue of $0.00. Analysts estimated a revenue of $1.02M. Earnings per share were $-0.11. Analysts had estimated an EPS of $-0.15.
Transenterix Inc (TRXC) made into the market gainers list on Wednesdays trading session with the shares advancing 1.46% or 0.02 points. Due to strong positive momentum, the stock ended at $1.39, which is also near the day’s high of $1.41. The stock began the session at $1.41 and the volume stood at 4,03,391 shares. The 52-week high of the shares is $6.1 and the 52 week low is $1.03. The company has a current market capitalization of $160 M and it has 11,50,00,060 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Anthony C. J. Fernando (Chief Technology Officer) purchased 27,000 shares at $1.46 per share price.Also, On Nov 18, 2015, Andrea Biffi (director) purchased 25,000 shares at $2.82 per share price.On Nov 16, 2015, Willam N Kelley (director) purchased 20,000 shares at $2.80 per share price, according to the Form-4 filing with the securities and exchange commission.
TransEnterix Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (the SurgiBot System). The Company’s SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System (the SPIDER System) a manual laparoscopic system in the United States Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.